Skip to Main Content

INFORMATION FOR

Mengni He

Characterizing resistance mechanisms for antibody-drug conjugates (ADCs) and designing diagnostic assays for ADC treatments: ADCs are a novel class of cancer therapy that links antibody specificity to potent cytotoxic molecules. Although showed significant improvement in clinical trials, ADCs still exhibit resistance and toxicities. Hence, I aim to investigate the resistance mechanisms for ADCs, identify predictive biomarkers for ADC responders, and design standardized and clinically applicable diagnostic assays for screening.

Mentor: David Rimm